Identify OTX2-interacting proteins repressing differentiation in medulloblastoma

鉴定抑制髓母细胞瘤分化的 OTX2 相互作用蛋白

基本信息

  • 批准号:
    8768857
  • 负责人:
  • 金额:
    $ 8.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-01 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Medulloblastoma, the most common type of pediatric brain malignancy, is an aggressive primitive neuroectodermal tumor arising from the cerebellum. It presents a significant cause of cancer-related death in children and current treatment of radio-chemotherapy impairs children's development and causes long-term adverse effects. Therefore, targeted therapies based on the molecular features of medulloblastoma are needed to minimize the treatment-related side effects in children. The transcription factor OTX2 is overexpressed and/or genomically amplified in most medulloblastomas. It is overexpressed in over 60% of medulloblastoma. Our previous study has identified OTX2 as a transcriptional repressor and a gatekeeper of myogenic and neuronal differentiation in medulloblastoma cells. The strong repressor activity exhibited by its homeobox domain (HD) renders OTX2 transcriptionally repressive. In medullomyoblastoma, a subtype of medulloblastoma with differentiated myogenic cells mixed with tumor cells, we have linked the loss of expression of OTX2 to the myogenic differentiation in tumor cell populations. Inducible knockdown of OTX2 by shRNA led to significant extension of survival in an orthotopic medulloblastoma xenograft model. Owing to the remarkable repressor activity displayed by the 60 amino acid OTX2-HD and its lack of functional motif related to transcriptional regulators, we hypothesize that this transcriptional repression is the result of interactions with epigenetic regulators. We therefore propose to test inhibitors of potential epigenetic regulators to characterize the nature of OTX2-HD mediated repression. We propose to perform in vivo crosslinking/immuno-purification/tandem mass spectrometry to identify binding partners of OTX2-HD. As a complementary strategy, we suggest additionally to use split-ubiquitin yeast two-hybrid system to identify novel interacting partners of OTX2-HD in a D425 medulloblastoma cDNA library. Subsequently, we will analyze and validate the interacting proteins in vitro and in vivo in medulloblastoma cells, and study the functionality of those binding proteins. In summary, understanding the molecular mechanism of OTX2 will advance our knowledge to develop targeted therapies that initiate the differentiation suppressed by OTX2 in medulloblastoma. This goal can be achieved by identifying the inhibitors of epigenetic regulators associated with OTX2- HD and by manipulating the potential interacting partners relevant in OTX2-mediated suppression of differentiation, which is the long term purpose of the study.
描述(申请人提供):髓母细胞瘤是最常见的儿童脑恶性肿瘤,是一种起源于小脑的侵袭性原始神经外胚层肿瘤。它是儿童癌症相关死亡的一个重要原因,目前的放化疗治疗损害儿童发育并造成长期不良影响。因此,需要根据成神经管细胞瘤的分子特征进行靶向治疗,以尽量减少儿童治疗相关的副作用。转录因子OTX2在大多数髓母细胞瘤中过度表达和/或基因组扩增。它在60%以上的髓母细胞瘤中过表达。我们之前的研究已经发现OTX2在成神经管细胞瘤细胞中是一种转录抑制因子和肌源性和神经元分化的守门人。其同源盒结构域(HD)表现出强烈的抑制活性,使OTX2具有转录抑制作用。髓母细胞瘤是髓母细胞瘤的一种亚型,分化的肌源性细胞与肿瘤细胞混合,我们已经将OTX2的表达缺失与肿瘤细胞群的肌源性分化联系起来。在原位髓母细胞瘤异种移植模型中,通过shRNA诱导敲低OTX2可显著延长存活时间。由于60个氨基酸的OTX2-HD表现出显著的抑制活性,并且缺乏与转录调节因子相关的功能基序,我们假设这种转录抑制是与表观遗传调节因子相互作用的结果。因此,我们建议测试潜在表观遗传调节因子的抑制剂,以表征OTX2-HD介导的抑制的性质。我们建议采用体内交联/免疫纯化/串联质谱法来鉴定OTX2-HD的结合伙伴。作为补充策略,我们建议另外使用分裂-泛素酵母双杂交系统来鉴定D425髓母细胞瘤cDNA文库中OTX2-HD的新相互作用伙伴。随后,我们将在体外和体内对成神经管细胞瘤细胞的相互作用蛋白进行分析和验证,并研究这些结合蛋白的功能。总之,了解OTX2的分子机制将提高我们的知识,开发靶向治疗,启动髓母细胞瘤中OTX2抑制的分化。这一目标可以通过鉴定与OTX2- HD相关的表观遗传调节因子的抑制剂,以及通过操纵OTX2介导的分化抑制相关的潜在相互作用伙伴来实现,这是本研究的长期目的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Renyuan Bai其他文献

Renyuan Bai的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Renyuan Bai', 18)}}的其他基金

Multimodal MRI for guiding bacterial cancer therapy
多模态 MRI 指导细菌癌症治疗
  • 批准号:
    10443928
  • 财政年份:
    2022
  • 资助金额:
    $ 8.1万
  • 项目类别:
Multimodal MRI for guiding bacterial cancer therapy
多模态 MRI 指导细菌癌症治疗
  • 批准号:
    10633262
  • 财政年份:
    2022
  • 资助金额:
    $ 8.1万
  • 项目类别:
Adrenergic modulation of cellular immune functions in CAR T cell-induced cytokine release syndrome
CAR T 细胞诱导的细胞因子释放综合征中细胞免疫功能的肾上腺素调节
  • 批准号:
    10532157
  • 财政年份:
    2020
  • 资助金额:
    $ 8.1万
  • 项目类别:
Adrenergic modulation of cellular immune functions in CAR T cell-induced cytokine release syndrome
CAR T 细胞诱导的细胞因子释放综合征中细胞免疫功能的肾上腺素调节
  • 批准号:
    10304166
  • 财政年份:
    2020
  • 资助金额:
    $ 8.1万
  • 项目类别:
Adrenergic modulation of cellular immune functions in CAR T cell-induced cytokine release syndrome
CAR T 细胞诱导的细胞因子释放综合征中细胞免疫功能的肾上腺素调节
  • 批准号:
    9921965
  • 财政年份:
    2020
  • 资助金额:
    $ 8.1万
  • 项目类别:
Identify OTX2-interacting proteins repressing differentiation in medulloblastoma
鉴定抑制髓母细胞瘤分化的 OTX2 相互作用蛋白
  • 批准号:
    8883429
  • 财政年份:
    2014
  • 资助金额:
    $ 8.1万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 8.1万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 8.1万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 8.1万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 8.1万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了